{"id":2544,"date":"2025-10-25T11:47:44","date_gmt":"2025-10-25T11:47:44","guid":{"rendered":"https:\/\/network.rvrising.com\/?p=2544"},"modified":"2025-10-25T11:47:44","modified_gmt":"2025-10-25T11:47:44","slug":"cardiovalve-completes-target-study-enrollment-for-ce-registration-study-for-tricuspid-valve-replacement","status":"publish","type":"post","link":"https:\/\/www.rvrising.com\/news\/business\/cardiovalve-completes-target-study-enrollment-for-ce-registration-study-for-tricuspid-valve-replacement\/","title":{"rendered":"Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement"},"content":{"rendered":"

The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch<\/span><\/b><\/p>\n

\n

HANGZHOU, China<\/span>, Oct. 25, 2025<\/span> \/PRNewswire\/ —\u00a0Venus\u00a0Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the “Company”) today announced the successful completion of patient enrollment in the Cardiovalve TARGET study<\/b> for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled<\/b>. The completion of enrollment marks a major milestone toward European regulatory approval for Cardiovalve’s Transcatheter Tricuspid Valve Replacement (TTVR) system<\/b>, the company’s flagship solution for treating tricuspid regurgitation.<\/p>\n

With enrollment now complete, the company is preparing to submit its CE Mark application<\/b> to European regulators later this year. Pending approval, commercial launch of the Cardiovalve TR system in Europe is projected for 2027<\/b>.<\/p>\n

Building on this achievement, Cardiovalve is also preparing to initiate its AHEAD study<\/b>, which will evaluate the safety and performance of Cardiovalve’s mitral valve replacement system<\/b> in patients suffering from significant mitral regurgitation (MR). The AHEAD study is designed to support a future CE Mark application<\/b> for the mitral system.<\/p>\n

Cardiovalve Participation at TCT 2025<\/b><\/p>\n

Cardiovalve will present preliminary data for its mitral regurgitation (MR) system at TCT 2025<\/b>.<\/p>\n

The presentation, titled “Transcatheter Mitral Valve Replacement Using the New Generation Cardiovalve System,” will be led by Dr. Christian Frerker.<\/b><\/p>\n

Session Details<\/b>:<\/p>\n